<DOC>
	<DOCNO>NCT00402441</DOCNO>
	<brief_summary>Primary Objective : - To demonstrate risedronate 35-mg weekly efficacious placebo increase maintain bone mineral density ( BMD ) lumbar spine 1 year treatment woman non-osteoporotic 0.5-5 year postmenopausal . Secondary objective : - To demonstrate risedronate 35-mg weekly efficacious placebo increase maintain total proximal femur , femoral neck , trochanter BMD 1 year treatment woman 0.5-5 year postmenopausal - To assess general safety 35-mg risedronate administer weekly .</brief_summary>
	<brief_title>Risedronate Prevention Osteoporosis Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>The following information clinical trial provide information purpose allow patient physician initial discussion trial . This information intend complete information trial , contain consideration may relevant potential participation trial , replace advice personal physician health professional . Main Inclusion/Exclusion criterion list hereafter : Inclusion criterion : Be postmenopausal 0.55 years.Menopause define 12 month without menses , base medical history . Subjects postmenopausal secondary bilateral oophorectomy must serum FSH &gt; 40 mIU/mL estradiol &lt; 20 pg/mL . Subjects 3 contiguous lumbar spine vertebral body ( L1L4 ) without fracture degenerative disease . Lumbar spine BMD mean value &gt; 0.772g/cm2 ( Hologic ) &gt; 0.880 g/cm2 ( Lunar ) . Exclusion criterion : Subjects adequate lumbar spine BMD osteoporotic total proximal femur BMD ( &lt; 0.637 g/cm2 [ Hologic ] ) &lt; 0.694 g/cm2 [ Lunar ] ) determine dualenergy xray absorptiometry ( DXA )</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>